Acurx Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | — | $2.5M |
| FY2020 | — | $2.7M | $3.2M |
| FY2021 | — | $12.4M | $13.0M |
| FY2022 | — | $7.3M | $9.1M |
| FY2023 | — | $4.7M | $7.5M |
| FY2024 | — | $615.1K | $3.7M |
| FY2025 | — | $5.3M | $7.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | — | $2.5M |
| FY2020 | — | $2.7M | $3.2M |
| FY2021 | — | $12.4M | $13.0M |
| FY2022 | — | $7.3M | $9.1M |
| FY2023 | — | $4.7M | $7.5M |
| FY2024 | — | $615.1K | $3.7M |
| FY2025 | — | $5.3M | $7.6M |